Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals
  4. Vaccines

COVID-19 Vaccines - Southeast Asia

Southeast Asia
  • The COVID-19 Vaccines market in Southeast Asia is expected to witness significant growth in the coming years.
  • According to projections, the revenue is estimated to reach a staggering US$1.76bn by 2024.
  • Moreover, it is anticipated that the market will exhibit a robust compound annual growth rate (CAGR) of -17.03% from 2024 to 2029.
  • This growth trajectory is predicted to result in a market volume of approximately US$691.80m by the end of 2029.
  • When comparing global markets, it is worth noting that United States is expected to generate the highest revenue in the COVID-19 Vaccines market.
  • In 2024 alone, United States is projected to generate a substantial revenue of US$4.39bn.
  • This highlights the significant market potential and commercial opportunities United States for COVID-19 Vaccines market.
  • Southeast Asian countries are experiencing a surge in demand for COVID-19 vaccines as they race to protect their populations from the virus.

Definition:
This market covers vaccines against COVID-19. Included are different types of vaccines (mRNA-based, viral vector vaccines).

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, Moderna, Biontech, Johnson & Johnson, AstraZeneca

In-Scope

  • COVID-19 vaccines
  • mRNA-based vaccines
  • Viral vector vaccines

Out-Of-Scope

  • Vaccines against other diseases
  • Antivirals
Pharmaceuticals: market data & analysis - Cover

Market Insights report

Pharmaceuticals: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The COVID-19 pandemic has created a surge in demand for vaccines globally, and Southeast Asia is no exception.

    Customer preferences:
    As in other regions, customers in Southeast Asia are looking for vaccines that are effective, safe, and affordable. However, there is also a strong preference for vaccines that are easy to store and transport, given the region's diverse geography and limited cold chain infrastructure.

    Trends in the market:
    Indonesia, the Philippines, and Vietnam are among the countries in Southeast Asia with the highest demand for COVID-19 vaccines. These countries have large populations and high infection rates, and are thus prioritizing vaccination efforts. In Indonesia, the Sinovac vaccine has been the most widely used, while the Philippines has been using a combination of Sinovac, AstraZeneca, and Pfizer-BioNTech vaccines. Vietnam has developed its own vaccine, called Nanocovax, which is currently in phase 3 clinical trials. In addition to these trends, there is also a growing interest in booster shots and vaccine mix-and-match strategies, as countries try to stay ahead of new variants and prolong immunity.

    Local special circumstances:
    One unique challenge in Southeast Asia is the presence of a large informal sector, which can make it difficult to track and vaccinate all eligible individuals. In addition, there are cultural and language barriers that can hinder communication and trust-building efforts. Furthermore, there are geopolitical tensions at play, as countries try to secure vaccine supplies from different sources and avoid becoming overly reliant on any one country or manufacturer.

    Underlying macroeconomic factors:
    The COVID-19 pandemic has had a significant impact on the economies of Southeast Asia, with many countries experiencing a contraction in GDP. As a result, there is a need to balance the cost of vaccines with other competing priorities, such as healthcare infrastructure and social welfare programs. In addition, the region's reliance on tourism and trade has been disrupted by the pandemic, further highlighting the need for a swift and effective vaccination campaign.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Pharmaceuticals: market data & analysis - BackgroundPharmaceuticals: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.